Secukinumab is associated with sustained improvement in patients' quality of life up to year 5: results of a randomized extension of the phase III erasure and fixture trials

被引：0

作者：

Langley, R. ^{[1
]}

Sigurgeirsson, B. ^{[2
]}

Szepietowski, J. ^{[3
]}

Tsai, T-F. ^{[4
]}

de Vera, A. ^{[5
]}

Charef, P. ^{[5
]}

Gilloteau, I. ^{[5
]}

You, R. ^{[6
]}

Hampele, I. ^{[5
]}

机构：

[1] Dalhousie Univ, Halifax, NS, Canada

[2] Univ Iceland, Reykjavik, Iceland

[3] Univ Med, Wroclaw, Poland

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] Novartis Pharma AG, Basel, Switzerland

[6] China Novartis Inst BioMed Res, Shanghai, Peoples R China

来源：

关键词：

Moderate to severe chronic plaque psoriasis; Patient reported outcomes; Quality of Life; Secukinumab;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P175

引用

页码：78 / 78

页数：1